Kiri

HRP/PCC/2024

Policy and Coordination Committee (PCC)

List of Members – 2024

Category (1) – Largest financial contributors in the previous (2022-2023) biennium (countries) *

Australia Canada China† Flemish Government, Belgium Netherlands Norway Sweden Switzerland Thailand United Kingdom of Great Britain and Northern Ireland United States of America

Category (2) – Countries elected by the WHO Regional Committees

China† 2024-2026 Indonesia 2022-2024 India 2024-2026 Italy 2022-2024 Mongolia 2023-2025 Morocco 2024-2026 Nicaragua 2022-2024 Senegal 2022-2024 Seychelles 2022-2024 Sierra Leone 2024-2026 South Africa 2024-2026 Timor-Leste 2023-2025 Tonga 2022-2024 Uruguay 2022-2024

* At its 16th meeting in June 2003, PCC endorsed the interpretation of section 2.2.1 of the Memorandum on the Administrative Structure of the Special Programme to mean that Category 1 membership should consist of representatives of the 11 largest donors not otherwise represented on the PCC under another category.

† In 2023 China was elected by the Regional Committee for the Western Pacific to serve as a member of PCC in category 2 for a three-year term.

…/…

HRP/PCC/2024 Category (3) – Other interested cooperating parties

Armenia 2023-2025 Chile 2024-2026

Category (4) – Permanent members

UNDP } UNFPA } UNICEF } Cosponsors WHO } The World Bank }

IPPF UNAIDS

Page 2

Saatja: EURO Governance <[email protected]>

Saadetud: 21.11.2024 12:51

Adressaat: EURO Governance <[email protected]>

Koopia: EURO Governance <[email protected]>; ALLOTEY, Pascale

<[email protected]>; MURCOTT, Jenny <[email protected]>

Teema: Applications for Category 3 membership, Special Programme of

Research, Development and Research Training in Human Reproduction (HRP)

Policy and Coordination Committee (PCC)

Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga.Tundmatu saatja

korral palume linke ja faile mitte avada.Tähelepanu! Tegemist on

välisvõrgust saabunud kirjaga.Tundmatu saatja korral palume linke ja

faile mitte avada.To the Member States of the WHO European Region

Dear Sir or Madam,

At the request of the Chief Scientist of WHO, this is to kindly invite

you to express interest in the vacant seat in category 3 membership of

the Policy and Coordination Committee (PCC) of the Special Programme of

Research, Development, and Research Training in Human Reproduction (HRP).

The Policy and Coordination Committee (PCC) is the governing body of the

UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research,

Development and Research Training in Human Reproduction (HRP).

The membership of PCC is described in paragraph 2.2 of the MOU, and

includes as category 3, two members elected by PCC for three-year terms

from interested remaining Cooperating Parties. The term of office of one

member in category 3 will come to an end on 31 December 2025. It will

therefore be necessary for an election to take place at the Thirty-eighth

meeting of PCC, which will take place in Geneva and on 29 and 30 April

2025.

The term of office of the newly-elected member will run from 1 January

2026 to 31 December 2028.

Under the terms of the HRP MOU, all governments are eligible for election

under category 3, except those that are already a member under Category 1

or Category 2.

For the European Region, the following Member States are members of the

PCC:

Category 1: Belgium (Flemish Government), Netherlands (Kingdom of the),

Norway, Sweden, Switzerland, United Kingdom of Great Britain and Northern

Ireland

Category 2: currently Italy followed by Romania starting from 1 January

2025

Category 3: Armenia

Applications should be sent by 27 February 2025 directly to Dr Pascale

Allotey, Director of the Special Programme ( and ), outlining the

motivation for applying, specifically noting work on family planning,

research and development and in human reproduction and fertility

regulation, as demonstrated by national policies and programmes.

Once the member is elected at the April 2025 meeting, an invitation will

be extended to the government/organization concerned to nominate their

representatives for the three-year term of office on PCC.

Should you have any queries on the process or the application

requirements, please do not hesitate and contact us.

Yours sincerely,

Regional Governance and Languages Team

Regional Governance and Languages Unit

Executive Directors DivisionWHO Regional Office for Europe Marmorvej 51,

DK-2100 Copenhagen ج DenmarkT: &#43;45 45 33 68 51

|

Òåìà: Âûäâèæåíèå êàíäèäàòóð (êàòåãîðèÿ 3) â ñîñòàâ Êîìèòåòà ïî ïîëèòèêå è

êîîðäèíàöèè Ñïåöèàëüíîé ïðîãðàììû íàó÷íûõ èññëåäîâàíèé, ðàçðàáîòîê è

ïîäãîòîâêè íàó÷íûõ êàäðîâ â îáëàñòè âîñïðîèçâîäñòâà íàñåëåíèÿ

Ãîñóäàðñòâàì-÷ëåíàì â Åâðîïåéñêîì ðåãèîíå ÂÎÇ

Óâàæàåìûå äàìû è ãîñïîäà!

Ïî ïîðó÷åíèþ ãëàâíîãî íàó÷íîãî ñîòðóäíèêà ÂÎÇ èìååì ÷åñòü ïðåäëîæèòü âàì

ñîîáùèòü î çàèíòåðåñîâàííîñòè âàøåé ñòðàíû â âûäâèæåíèè êàíäèäàòóðû íà

âàêàíòíîå ìåñòî (êàòåãîðèÿ 3) â Êîìèòåòå ïî ïîëèòèêå è êîîðäèíàöèè

Ñïåöèàëüíîé ïðîãðàììû íàó÷íûõ èññëåäîâàíèé, ðàçðàáîòîê è ïîäãîòîâêè

íàó÷íûõ êàäðîâ â îáëàñòè âîñïðîèçâîäñòâà íàñåëåíèÿ.

Êîìèòåò ïî ïîëèòèêå è êîîðäèíàöèè ýòî ðóêîâîäÿùèé îðãàí Ñïåöèàëüíîé

ïðîãðàììû ÏÐÎÎÍ, ÞÍÔÏÀ, ÞÍÈÑÅÔ, ÂÎÇ è Âñåìèðíîãî áàíêà ïî íàó÷íûì

èññëåäîâàíèÿì, ðàçðàáîòêàì è ïîäãîòîâêå íàó÷íûõ êàäðîâ â îáëàñòè

âîñïðîèçâîäñòâà íàñåëåíèÿ.

Óñëîâèÿ ÷ëåíñòâà â Êîìèòåòå ïî ïîëèòèêå è êîîðäèíàöèè îïèñàíû â ïóíêòå

2.2 Ìåìîðàíäóìà î âçàèìîïîíèìàíèè. Â êàòåãîðèè 3 Êîìèòåò ïî ïîëèòèêå è

êîîðäèíàöèè èçáèðàåò äâóõ ÷ëåíîâ, ïðåäñòàâëÿþùèõ îñòàëüíûå

çàèíòåðåñîâàííûå Ñîòðóäíè÷àþùèå ñòîðîíû, ñðîêîì íà òðè ãîäà. Ñðîê

ïîëíîìî÷èé îäíîãî äåéñòâóþùåãî ÷ëåíà â êàòåãîðèè 3 èñòåêàåò 31 äåêàáðÿ

2025 ã. Ïîýòîìó íà òðèäöàòü âîñüìîì ñîâåùàíèè Êîìèòåòà ïî ïîëèòèêå è

êîîðäèíàöèè, êîòîðîå ñîñòîèòñÿ â Æåíåâå 2930 àïðåëÿ 2025 ã., íåîáõîäèìî

áóäåò âûáðàòü íîâîãî ÷ëåíà Êîìèòåòà.

Ñðîê ïîëíîìî÷èé íîâîèçáðàííîãî ÷ëåíà ïðîäëèòñÿ ñ 1 ÿíâàðÿ 2026 ã. ïî 31

äåêàáðÿ 2028 ã.

Ñîãëàñíî Ìåìîðàíäóìó î âçàèìîïîíèìàíèè â îòíîøåíèè Ñïåöèàëüíîé ïðîãðàììû

íàó÷íûõ èññëåäîâàíèé, ðàçðàáîòîê è ïîäãîòîâêè íàó÷íûõ êàäðîâ â îáëàñòè

âîñïðîèçâîäñòâà íàñåëåíèÿ, âûäâèãàòü ñâîè êàíäèäàòóðû â ðàìêàõ êàòåãîðèè

3 ìîãóò âñå ãîñóäàðñòâà, çà èñêëþ÷åíèåì òåõ, êîòîðûå óæå âõîäÿò â ñîñòàâ

Êîìèòåòà â ðàìêàõ êàòåãîðèé 1 èëè 2.

 ñîñòàâ Êîìèòåòà ïî ïîëèòèêå è êîîðäèíàöèè âõîäÿò ñëåäóþùèå ãîñóäàðñòâà-

÷ëåíû â Åâðîïåéñêîì ðåãèîíå:

Êàòåãîðèÿ 1: Áåëüãèÿ (Ïðàâèòåëüñòâî Ôëàíäðèè), Íèäåðëàíäû (Êîðîëåâñòâî),

Íîðâåãèÿ, Ñîåäèíåííîå Êîðîëåâñòâî Âåëèêîáðèòàíèè è Ñåâåðíîé Èðëàíäèè,

Øâåéöàðèÿ è Øâåöèÿ

Êàòåãîðèÿ 2: â íàñòîÿùåå âðåìÿ Èòàëèÿ, êîòîðóþ 1 ÿíâàðÿ 2025 ã. ñìåíèò

Ðóìûíèÿ

Êàòåãîðèÿ 3: Àðìåíèÿ

Çàÿâêè îò êàíäèäàòîâ äîëæíû áûòü íå ïîçæå 27 ôåâðàëÿ 2025 ã. íàïðàâëåíû

ä-ðó Pascale Allotey, äèðåêòîðó Ñïåöèàëüíîé ïðîãðàììû ( è ). Â çàÿâêå

äîëæíû áûòü èçëîæåíû ìîòèâû âûäâèæåíèÿ êàíäèäàòóðû, ñ îñîáûì âíèìàíèåì ê

ïðîâîäèìîé ñòðàíîé ðàáîòå â ñôåðå ïëàíèðîâàíèÿ ñåìüè, íàó÷íûõ

èññëåäîâàíèé è ðàçðàáîòîê, âîñïðîèçâîäñòâà íàñåëåíèÿ è ðåãóëèðîâàíèÿ

ôåðòèëüíîñòè, âêëþ÷àÿ ïðèìåðû ñîîòâåòñòâóþùèõ ãîñóäàðñòâåííûõ ñòðàòåãèé è

ïðîãðàìì.

Ïîñëå èçáðàíèÿ ÷ëåíà Êîìèòåòà ïî ïîëèòèêå è êîîðäèíàöèè íà ñîâåùàíèè â

àïðåëå 2025 ã. ïðàâèòåëüñòâó/îðãàíèçàöèè èç ñîîòâåòñòâóþùåé ñòðàíû áóäåò

íàïðàâëåíî ïðåäëîæåíèå î íàçíà÷åíèè ñâîåãî ïðåäñòàâèòåëÿ â ñîñòàâ

Êîìèòåòà ñðîêîì íà òðè ãîäà.

Åñëè ó âàñ âîçíèêíóò êàêèå-ëèáî âîïðîñû îòíîñèòåëüíî ïðîöåññà èëè

òðåáîâàíèé ê ïðåäñòàâëåíèþ êàíäèäàòóð, ïðîñüáà áåç êîëåáàíèé îáðàùàòüñÿ ê

íàì.

Ñ óâàæåíèåì,

Ïîäðàçäåëåíèå ðåãèîíàëüíîãî ñòðàòåãè÷åñêîãî ðóêîâîäñòâà è ëèíãâèñòè÷åñêîé

ïîääåðæêè

Ïîäðàçäåëåíèå ðåãèîíàëüíîãî ñòðàòåãè÷åñêîãî ðóêîâîäñòâà è

ëèíãâèñòè÷åñêîé ïîääåðæêè

Îòäåë Èñïîëíèòåëüíîãî äèðåêòîðàÅâðîïåéñêîå ðåãèîíàëüíîå áþðî

ÂÎÇ Marmorvej 51, DK-2100 Copenhagen Ø, DenmarkÒåë.: &#43;45 45 33 68 51

|

M E M O R A N D U M

From: Chief Scientist,

Science Division

To: Regional Director,

EURO

Date: 18 October 2024

Our ref: Attention:

Your ref: H9-87-34 Through:

Originator: Dr Pascale Allotey,

Director, SRH

Subject: SPECIAL PROGRAMME OF RESEARCH,

DEVELOPMENT AND RESEARCH TRAINING

IN HUMAN REPRODUCTION (HRP), POLICY

AND COORDINATION COMMITTEE (PCC),

APPLICATIONS FOR CATEGORY (3)

MEMBERSHIP

The Policy and Coordination Committee (PCC) is the governing body of the

UNDP/UNFPA/UNICEF/WHO/World Bank Special Programme of Research, Development

and Research Training in Human Reproduction (HRP). Attached for your information is a

copy of the Memorandum on the Administrative Structure of the Special Programme (HRP

MOU), which defines the structure, functions and mode of operation of HRP, including the

membership of PCC. Also attached, for your information, is the current list of PCC members

in 2024.

The membership of PCC is described in paragraph 2.2 of the MOU, and includes as

category 3, two members elected by PCC for three-year terms from interested remaining

Cooperating Parties. The term of office of one member in category 3 will come to an end on

31 December 2025. It will therefore be necessary for an election to take place at the Thirty-

eighth meeting of PCC, which will take place in Geneva and on 29 and 30 April 2025.

In accordance with the terms of the HRP MOU, all governments in the European

Region, except those that may be listed as a category 1 or category 2 member, are eligible for

election under category 3. The term of office of the newly-elected member will run from

1 January 2026 to 31 December 2028.

In accordance with paragraph 2.2 of the HRP MOU, PCC members may be re-elected.

ENCLS: (2)

cc: Director, Division of Country Health Policies and Systems (CPS), EURO

Page 2

I would be grateful if you would take the necessary action within your Region to

solicit applications for category 3 membership for among the above-mentioned eligible

governments by 27 February 2025, which is 60 days before the start of the Thirty-eighth

meeting of PCC and the deadline for the receipt of applications.

Applications should be sent directly to Dr Pascale Allotey, Director of the Special

Programme ([email protected] and [email protected]), outlining the motivation for applying,

specifically noting work on family planning, research and development and in human

reproduction and fertility regulation, as demonstrated by national policies and programmes.

If candidatures are received by the WHO Representatives or by the Regional Office,

the date of receipt must immediately be stamped on the incoming correspondence, and

be forwarded to HRP by e-mail ([email protected]) to avoid postal delays.

Once the member is elected at the April 2025 meeting, an invitation will be extended

to the government/organization concerned to nominate their representatives for the three-year

term of office on PCC.

Thanking you for your timely action in regard of the above.

Dr Jeremy Farrar

Chief Scientist

HRP/1988/1(rev. 2012) ORIGINAL: ENGLISH

Memorandum on the Administrative Structure of the Special Programme of Research, Development and

Research Training in Human Reproduction (HRP)1

The Special Programme of Research, Development and Research Training in Human Reproduction (hereinafter called the Special Programme, or HRP) is structured on the basis of cosponsorship by the United Nations Development Programme (hereinafter called UNDP), the United Nations Population Fund (hereinafter called UNFPA), the United Nations Children’s Fund (hereinafter called UNICEF), the World Health Organization (hereinafter called WHO), the International Bank for Reconstruction and Development (hereinafter called The Bank), and operates within a broad framework of intergovernmental and interagency cooperation and participation.

1. Basic structure

1.1 The Special Programme is a global programme of international technical cooperation initiated by WHO to promote, coordinate, support, conduct and evaluate research in human reproduction, with particular reference to the needs of developing countries, by:

(i) promoting and supporting research aimed at finding and developing safe and

effective methods of fertility regulation, and identifying and eliminating obstacles to such research and development;

(ii) identifying and evaluating health and safety problems associated with fertility

regulation technology, analysing the behavioural and social determinants of fertility regulation, and testing cost-effective interventions to develop improved approaches to fertility regulation within the context of reproductive health services;

(iii) strengthening the training and research capability of developing countries in the

field of human reproduction;

(iv) establishing a basis for collaboration with other programmes engaged in research

and development in human reproduction, which will include the identification of priorities across the field and the coordination of activities in the light of such priorities.

1 Amended by the Co-sponsoring Agencies in agreement with the Twenty-fifth Session of Policy and Coordination Committee in 2012, with effect

from 1 December 2012.

HRP/1988/1(rev. 2012)

Page 2

1.2 The Cooperating Parties are:

1.2.1 Governments contributing to Special Programme resources; governments

providing technical and/or scientific support to the Special Programme; and governments with policies designed to address the needs for fertility regulation and family planning for their populations in the context of their overall plans for health care and social and economic development.

1.2.2 Intergovernmental organizations, United Nations Funds and Programmes, and

other non-profit-making organizations contributing to Special Programme Resources or providing technical and scientific support to the Special Programme.

1.3 The Cosponsors are UNDP, UNFPA, UNICEF, WHO and The Bank.

1.4 The Executing Agency is WHO.

1.5 Special Programme Resources are the financial resources made available to the

Special Programme by governments and organizations through the WHO Voluntary Fund for Health Promotion.

2. Policy and Coordination Committee

The Policy and Coordination Committee (PCC) is the governing body of the Special Programme.

2.1 Functions

PCC shall, for the purpose of coordinating the interests and responsibilities of the

parties cooperating in the Special Programme, have the following functions:

2.1.1 To review and decide upon the planning and execution of the Special

Programme. For this purpose it will keep itself informed of all aspects of the development of the Special Programme and consider reports and recommendations submitted to it by the Standing Committee referred to in Section 3 of this Memorandum (hereinafter called the Standing Committee), the Executing Agency and the Scientific and Technical Advisory Group referred to in Section 4 of this Memorandum (hereinafter called STAG).

2.1.2 To review and approve the plan of action and budget for the coming financial

period prepared by the Executing Agency and reviewed by STAG and the Standing Committee.

2.1.3 To review the proposals of the Standing Committee and approve

arrangements for the financing of the Special Programme.

2.1.4 To review proposed longer term plans of action and their financial implications.

2.1.5 To review the annual financial statements submitted by the Executing Agency,

and the audit report thereon submitted by the External Auditor of the Executing Agency.

2.1.6 To review periodic reports that will evaluate the progress of the Special

Programme towards the achievement of its objectives.

HRP/1988/1(rev. 2012)

Page 3

2.1.7 To review and endorse the selection of members of STAG by the Executing Agency in consultation with the Standing Committee.

2.1.8 To consider such other matters relating to the Special Programme as may be

referred to it by any Cooperating Party.

2.2 Membership

PCC shall consist of 34 members from among the Cooperating Parties as follows:

2.2.1 Largest financial contributors: 11 government representatives from the

countries that were the largest financial contributors to the Special Programme in the previous biennium.

2.2.2 Countries elected by the WHO regional committees: 14 government

representatives from Member States elected by the WHO regional committees for three-year terms according to population distribution and regional needs, distributed as follows:

Africa 4 Americas 2 South-east Asia 3 Europe 1 Eastern Mediterranean 1 Western Pacific 3

In these elections due account should be taken of a country's financial and/or technical support to the Special Programme and its interest in the fields of family planning, research and development and in human reproduction and fertility regulation, as demonstrated by national policies and programmes.

2.2.3 Other interested Cooperating Parties: two members elected by PCC for

three-year terms from the remaining Cooperating Parties.

2.2.4 Permanent members: the Cosponsors of the Special Programme,the

International Planned Parenthood Federation and the Joint United Nations Programme on HIV/AIDS.

Members of PCC in categories 2.2.2 and 2.2.3 may be re-elected.

2.3 Observers

Other Cooperating Parties may be represented as observers with the approval of the

Executing Agency after consultation with the Standing Committee. Observers attend sessions of PCC at their own expense.

2.4 Operation

2.4.1 PCC shall meet at least once a year, and in extraordinary sessions, if

required, subject to the agreement of the majority of its members. The Executing Agency shall provide the secretariat.

2.4.2 PCC shall elect each year from among its members, a chairman, a vice-

chairman and a rapporteur.

HRP/1988/1(rev. 2012)

Page 4

2.4.3 The Chairman shall:

• convene and preside over sessions of PCC; • undertake such additional duties as may be assigned by PCC.

2.4.4 Subject to any special arrangements that may be decided upon by PCC,

members of PCC shall make their own arrangements to cover the expenses incurred in attending sessions of PCC.

2.5 Procedures

2.5.1 In its proceedings PCC shall be guided mutatis mutandis by the Rules of

Procedure of the World Health Assembly.

2.5.2 In consultation with the Chairman, the secretariat shall prepare an annotated

provisional agenda for each session.

2.5.3 A report, prepared by the Rapporteur with the assistance of the secretariat,

shall be circulated as soon as possible after the conclusion of the session for the approval of participants.

3. The Standing Committee 3.1 Composition

The Standing Committee shall be comprised of representatives of the Cosponsors.

3.2 Functions

The Standing Committee shall have the following functions:

3.2.1 To review plans of action and a budget for the coming financial period,

prepared by the Executing Agency and reviewed by STAG, in time for presentation to the annual session of PCC.

3.2.2 To make proposals to PCC for the financing of the Special Programme for the

coming financial period.

3.2.3 To review the reallocation of resources during a financial period, as

recommended by STAG and the Executing Agency, and to report to PCC.

3.2.4 To examine the reports submitted to the Executing Agency by STAG and the

Executing Agency's comments; make the necessary observations thereon; and transmit these, with comments as appropriate, to PCC.

3.2.5 To review particular aspects of the Special Programme, including those that

may be referred to it by PCC, and present findings and recommendations to PCC.

3.2.6 To inform PCC, as required, regarding Special Programme matters of interest

to PCC.

3.2.7 To prepare an annual report of its activities for PCC.

HRP/1988/1(rev. 2012)

Page 5

3.3 Operation

3.3.1 The Standing Committee shall usually meet twice a year; once at the time of

the PCC session, and additionally between sessions of PCC.

3.3.2 The Executing Agency shall arrange for support services and facilities as may

be required by the Standing Committee.

3.3.3 Members of the Standing Committee shall make their own arrangements to

cover the expenses incurred in attending meetings of the Standing Committee.

4. Scientific and Technical Advisory Group (STAG) 4.1 Functions

STAG shall have the following functions:

4.1.1 To review, from a scientific and technical standpoint, the content, scope and

dimensions of the Special Programme, including the research areas covered and approaches to be adopted.

4.1.2 To recommend priorities within the Special Programme, including the

establishment and disestablishment of task forces, and all scientific and technical activities related to the Special Programme.

4.1.3 To provide PCC and the Standing Committee with a continuous and

independent evaluation of the scientific and technical aspects of all activities of the Special Programme.

4.1.4 To review the plans of action and the budget for financial periods prepared by

the Executing Agency and make proposals to the Standing Committee for possible reallocation of resources within the scientific and technical component of the Special Programme during each financial period.

For these purposes, STAG may propose and present for consideration to the Executing Agency, the Standing Committee or PCC, as appropriate, such technical documents and recommendations as it deems necessary.

4.2 Composition

4.2.1 STAG shall have 15-18 members, who shall serve in their personal capacities

to represent the broad range of biomedical and other disciplines required for Special Programme activities.

4.2.2 Members of STAG, including the Chairman, shall be selected, on the basis of

scientific and technical competence, by the Executing Agency, in consultation with the Standing Committee and with the endorsement of PCC.

4.2.3 Members of STAG shall not be members of other committees of the Special

Programme, principal investigators in studies undertaken by the Special Programme, or Special Programme grantees.

HRP/1988/1(rev. 2012)

Page 6

4.2.4 Members of STAG, including the Chairman, shall be appointed to serve for a period of three years, and shall be eligible for immediate reappointment only once.

4.3 Operation

4.3.1 STAG shall meet at least once each year.

4.3.2 The Executing Agency shall provide the secretariat of STAG, including

sustained scientific, technical and administrative support.

4.3.3 STAG shall elect a vice-chairman and a rapporteur for each meeting from

among its members.

4.3.4 STAG shall prepare an annual report on the basis of a full review of all

technical and scientific aspects of the Special Programme. This report, containing its findings and recommendations, shall be submitted to the Executing Agency and to the Standing Committee. The Executing Agency shall submit its comments on the report (if any) to the Standing Committee. The Standing Committee shall then transmit the report, including any comments of the Executing Agency, together with its own observations and recommendations, to PCC. The Chairman of STAG, or in the absence of the Chairman a member of STAG acting as deputy, shall attend all sessions of PCC.

5. The Executing Agency

The Executing Agency, after consultation with the Standing Committee and other consultations as appropriate, shall appoint the Director, Special Programme, and appoint or assign all other personnel to the Special Programme, as specified in the plans of work. Drawing, as required, on the administrative resources of the Executing Agency, and in cooperation with the Cosponsors, the Assistant Director-General supervising the Director, Special Programme will be responsible for the overall management of the Special Programme. Drawing to the full on the scientific and technical resources of the Executing Agency, the Director, Special Programme shall be responsible for the overall scientific and technical development and operation of the Special Programme, including the plans of action and the budget.

= = =